Analysts’ Weekly Ratings Changes for PepGen (PEPG)

A number of firms have modified their ratings and price targets on shares of PepGen (NASDAQ: PEPG) recently:

• 5/31/2022 – PepGen is now covered by analysts at Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.
• 5/31/2022 – PepGen is now covered by analysts at SVB Leerink LLC. They set an “outperform” rating and a $40.00 price target on the stock.
• 5/31/2022 – PepGen is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $24.00 price target on the stock.
• 5/31/2022 – PepGen is now covered by analysts at Bank of America Co.. They set a “buy” rating and a $16.00 price target on the stock.

PepGen stock opened at $12.01 on Monday. PepGen Inc. has a 1-year low of $7.82 and a 1-year high of $16.99.

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD).

Featured Stories

• Get a free copy of the StockNews.com research report on PepGen (PEPG)
• Ride Out The Recession With These Dividend Kings 
• MarketBeat: Week in Review 6/13 – 6/17
• eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
• Honda’s Stock Continues To Fly Under The Radar
• Vuzix Stock Stays Optimistic

Want More Great Investing Ideas?